Brain Energy & Nootropic Neuroscience · · 22 min read · By

Dihexa vs Methylene Blue for Brain Fog & Cognitive Energy: The 2026 UK Review

Dihexa vs methylene blue for brain fog and cognitive energy - 2026 UK evidence review illustration showing a mitochondrion, the electron transport chain, a brain and a blue droplet

A blue dye older than aspirin has become the biohacking world’s obsession — and it is being sold for your mind, not your microscope. Searches for methylene blue spiked in early 2025 after it appeared in viral wellness videos — including a widely shared clip of a US politician adding a blue liquid to a drink — and it is now marketed to executives, students, shift workers and longevity enthusiasts as a mitochondrial nootropic for focus and energy. At the same time, people fighting brain fog keep finding Dihexa, a synaptogenic peptide that modulates the HGF/c-Met pathway, and asking which of the two they should try. This 2026 UK review puts them side by side. The short version: methylene blue has a real mechanism, a licensed-medicine history and one suggestive human imaging study — but the hype has sprinted far ahead of the evidence, and it carries drug-interaction and purity risks that Dihexa does not. Dihexa, meanwhile, has no completed human trials at all. Neither belongs at the front of a sensible plan for a clearer mind.

Not medical advice. Dihexa (PNB-0408) is an unscheduled research chemical, not an approved treatment for brain fog or any other condition. Methylene blue is a prescription medicine for specific uses (such as methaemoglobinaemia), not an approved cognitive enhancer, and the “biohacking” product sold online is frequently non-pharmaceutical grade. This page is general information, not a recommendation to take any product — and this site does not sell methylene blue. Nothing here is medical advice. If you have persistent brain fog, the right first step is a proper assessment with your GP. Read the full legal disclaimer.

Key Findings: Dihexa vs Methylene Blue for Brain Fog & Cognitive Energy

  • Two different tools: Methylene blue tunes the mitochondrial power supply (electron transport chain, cytochrome c oxidase, ATP); Dihexa is proposed to build synapses via HGF/c-Met. Energy versus wiring — not the same job.
  • Methylene blue has one suggestive human study: A 2016 Radiology fMRI study found a single low dose raised activity in attention and memory networks and lifted memory retrieval ~7% — small, but real human data.
  • A licensed-drug lineage: Methylene blue’s tau-inhibitor derivative hydromethylthionine (HMTM/LMTM, TauRx) reached Phase 3 for Alzheimer’s and a 2024 UK MHRA application — contested, but real late-stage work.
  • Dihexa has none of that: There is no completed human trial of Dihexa for brain fog, cognitive energy or any related complaint. The Benoist 2014 data is in animals and cells.
  • The viral moment ran ahead of the science: The 2025 methylene blue trend was driven by influencers, not new trials. Popularity is not proof.
  • Real methylene blue risks: It inhibits MAO-A, so mixing it with SSRIs/SNRIs, triptans or MAOIs risks serotonin syndrome — an FDA safety warning. G6PD deficiency and non-pharmaceutical purity are further hazards.
  • Dihexa’s own red flags: An unknown safety profile and a pro-proliferative c-Met mechanism — a specific cancer-relevant concern — while its closest drug relative, fosgonimeton, missed its Alzheimer’s Phase 3.
  • Bottom line: Methylene blue is the better-pedigreed of the two, but it is a genuine drug with genuine interactions, not a casual supplement — and Dihexa is an unlicensed peptide with no human efficacy data. Fix sleep, exercise and diet first; treat any medical cause; and keep both of these well down the list.

Methylene Blue in 2026: From Lab Dye to “Mitochondrial Nootropic”

Methylene blue was first synthesised in 1876 as a textile dye, became the first fully synthetic drug used in medicine, and has spent a century as a reliable treatment for methaemoglobinaemia, a surgical marker dye, and a laboratory stain. In 2026 it is being sold as something else entirely: a brain drug. The turn was swift and social. Searches jumped sharply in early 2025 after methylene blue featured in viral wellness content — including a much-shared video of a prominent US figure appearing to add a blue liquid to a drink — and after repeated endorsements from high-profile podcasters and longevity influencers. Almost overnight, a 150-year-old dye became one of the year’s hottest “brain optimisation” trends.

That audience overlaps almost perfectly with this site’s. The people buying blue tinctures for sharper focus are the same high performers — executives, founders, students, shift workers and biohackers — who bump into Dihexa marketed in overlapping communities as a “synaptogenic” cognitive booster. So the question arrives naturally: if you want a clearer, more energetic mind, should you reach for the dropper of methylene blue or the vial of research-grade peptide? Unusually for this series, one of the two actually has a coherent mechanism and a thread of human data. The other does not. This review explains exactly where each sits — and why “better than Dihexa” is a very low bar.

What Methylene Blue Actually Is — and Why the Brain Cares

Methylene blue (methylthioninium chloride) is a redox-cycling molecule: it can readily donate and accept electrons, flipping between an oxidised blue form and a reduced colourless form. That single chemical trick is the source of nearly everything interesting it does in the brain.

The mechanism is all about energy. Every thought, memory trace and second of focus is paid for in adenosine triphosphate (ATP), generated by mitochondria running electrons down the electron transport chain. When that chain is sluggish — through ageing, stress, poor sleep, low oxygen or metabolic strain — ATP production falls and the brain feels foggy and flat. At low doses, methylene blue acts as an alternative electron carrier: it accepts electrons upstream and delivers them directly to cytochrome c oxidase (Complex IV), effectively bypassing bottlenecks and keeping the energy line moving. In animal work, a single dose raised brain cytochrome oxidase activity substantially, and it also increases cerebral oxygen consumption and blood flow, as reviewed by Rojas, Bruchey and Gonzalez-Lima (2012). It has antioxidant properties and, at higher concentrations, inhibits the aggregation of tau protein — the basis of an entire Alzheimer’s drug programme discussed below.

Crucially, unlike most supplements, methylene blue crosses the blood-brain barrier easily and concentrates in brain tissue. That is genuinely unusual and part of why it is taken seriously. But hold the key point for the Dihexa comparison: methylene blue works by improving the energy supply to circuits that already exist. It is metabolic tuning, not rewiring — and that is a very different claim from the one Dihexa makes.

The Human Evidence for Methylene Blue and Cognition

Here is where methylene blue separates itself from most viral nootropics, and certainly from Dihexa: there is at least some real human data, even if it is thinner than the internet implies.

The 2016 fMRI study: the headline result

The single most-cited piece of human evidence came in 2016, when Rodriguez, Gonzalez-Lima and colleagues published in Radiology a randomised, double-blind, placebo-controlled fMRI study of 26 healthy adults. A single low oral dose of methylene blue increased functional MRI activity in the insular cortex during a sustained-attention task, boosted activity across the encoding, maintenance and retrieval networks during a short-term-memory task, and produced roughly a 7% increase in correct responses during memory retrieval versus placebo. This is a clean, if small, demonstration that a low dose measurably changes the working human brain — and it maps onto the energy-and-attention mechanism nicely.

The honest limits of that evidence

But one 26-person imaging study is not a treatment trial. It measured brain activity and a single memory task in healthy volunteers — not brain fog, not fatigue, not real-world performance over weeks, and not in the stressed or unwell people who actually search for help. There is preclinical evidence for neuroprotection and memory in animal models, and small studies in other contexts, but the cognitive-enhancement literature in humans remains limited and short-term. As a University of South Carolina pharmacologist put it in a 2025 explainer for The Conversation, the science is far more preliminary than the viral marketing suggests. The mechanism is real; the proof that it reliably clears brain fog in people is not yet there.

The simplified picture. Methylene blue has a plausible mechanism and one suggestive human imaging study — a genuinely different evidential world from “promising in mice.” But “one small fMRI study in healthy adults” is also a long way from “proven brain-fog treatment.” Both things are true at once.

The Alzheimer’s Drug Hiding Inside Methylene Blue: TauRx, LUCIDITY & the MHRA

There is a striking wrinkle that most biohacking coverage misses. Methylene blue’s tau-aggregation-inhibiting chemistry has been developed into an actual pharmaceutical: hydromethylthionine mesylate (HMTM), also known as LMTM, LMTX or TRx0237 — a stabilised, reduced form of methylthioninium developed by TauRx. It has been through large Phase 3 Alzheimer’s trials, including the LUCIDITY study.

The results are genuinely contested, and worth stating carefully. In earlier Phase 3 trials, the drug missed conventional primary endpoints when added to standard Alzheimer’s medication. TauRx has since reported that at a low dose, patients showed sustained cognitive and functional benefits over two years — around 71% of treated patients maintaining or improving their global rating versus about 52% on matched placebo in its analyses — and in July 2024 submitted a UK MHRA marketing authorisation application, with the drug designated for the Innovative Licensing and Access Pathway. Independent reviewers remain cautious, chiefly because the low-dose comparator complicates interpretation of what is “treatment” versus “control.”

Why does this matter for the Dihexa comparison? Because it shows the difference in seriousness between the two molecules. A methylene-blue-derived compound has been manufactured to pharmaceutical standard, tested in thousands of patients, published, scrutinised and put in front of a regulator — and even that rigorous programme produced disputed, hard-to-interpret results. Dihexa has nothing remotely comparable. If a purpose-built, professionally trialled relative of methylene blue still struggles to prove itself, the idea that an unregulated peptide from a research-chemical vial will quietly outperform it does not survive contact with the evidence.

Where Dihexa Enters: A Different Mechanism, a Thinner Evidence Base

Now the other side of the comparison. Dihexa (PNB-0408) is a small peptide derived from angiotensin IV, developed as a positive modulator of the HGF/c-Met pathway. Hepatocyte growth factor (HGF), acting on its receptor c-Met, drives synaptogenesis — the formation of new synaptic connections — through the PI-3K/AKT and MAPK cascades, and MET signalling remains active in the adult hippocampus and prefrontal cortex. In the original Benoist 2014 JPET work, Dihexa improved learning in rodent models and its effects depended on the HGF/Met system.

Compare the two mechanisms directly and the contrast is clean:

  • Methylene blue = energy. It tunes the mitochondrial power supply so existing circuits fire more efficiently. Fast-acting, metabolic, and with a genuine human imaging signal.
  • Dihexa = wiring. It is proposed to build new synapses via growth-factor signalling — a slower, structural, plasticity-based idea, conceptually adjacent to BDNF.

On paper, “builds new synapses” sounds more powerful than “charges the battery.” But there is a decisive asymmetry: methylene blue’s modest claim is anchored by a licensed-medicine history, a human fMRI study and a Phase 3 drug lineage, while Dihexa’s grander claim rests almost entirely on animal and cell data. There is no completed, published human efficacy trial of Dihexa for brain fog, cognitive energy, memory or focus. A mechanism that dazzles in a slide deck is not the same as a benefit demonstrated in people — a distinction the research and studies page returns to repeatedly.

Head to Head: Methylene Blue vs Dihexa on the Things That Matter

Stripped of hype, a fair comparison comes down to a handful of practical axes.

Evidence

Methylene blue: a century of medical use in other indications, a supportive 2016 human fMRI study, animal neuroprotection data, and a Phase 3 drug derivative. Dihexa: pre-clinical only; no completed human trial in any cognitive indication. Methylene blue wins this axis clearly — though its cognitive-enhancement proof is still thin.

Safety

Methylene blue: well-characterised at medical doses, but with three real cautions — it inhibits MAO-A (serotonin-syndrome risk with SSRIs/SNRIs, triptans, tramadol and MAOIs, per the FDA warning), it can cause haemolysis in G6PD deficiency, and online product is often non-pharmaceutical grade. Dihexa: unknown long-term safety, no pharmaceutical-grade quality control on “research chemical” material, and a mechanism that amplifies the pro-proliferative c-Met pathway — an oncologically relevant concern. Both carry real risk; they are simply different risks.

Legality & access

Methylene blue: a licensed prescription medicine in the UK for specific medical uses (such as methaemoglobinaemia); selling or marketing it as a cognitive enhancer is not authorised, and the “biohacking” supply chain sits outside medicines regulation. Dihexa: not a controlled drug, but not a licensed medicine either; it cannot lawfully be marketed or sold to treat brain fog or enhance cognition under MHRA rules, and personal-use possession sits in a grey zone set out on the UK legal status page.

Cost & quality

Methylene blue: cheap as a chemical, but pharmaceutical-grade material and honest sourcing are the whole game — ingesting lab- or industrial-grade dye is genuinely dangerous. Dihexa: expensive research-grade peptide of uncertain purity. In both cases, what you actually receive in the post is the real risk.

The honest scorecard. Methylene blue leads Dihexa on evidence, mechanism and pedigree. But “leads Dihexa” is not the same as “proven and safe.” Methylene blue is a real drug with real interactions, and Dihexa is an unlicensed peptide with no human efficacy data and a cancer-relevant flag. A win on the scoreboard does not make either a sensible first move.

The Clinical Parallels: Why Both Mechanisms Deserve Humility

There is a neat symmetry worth sitting with. Each of these compounds has a “serious drug” cousin that went through proper Phase 3 testing — and neither delivered a clean win.

Methylene blue’s cousin is hydromethylthionine (TauRx), which missed conventional endpoints and now rests on a contested low-dose signal and a pending regulatory application. Dihexa’s cousin is fosgonimeton (ATH-1017), developed by Athira Pharma as a small-molecule positive modulator of the same HGF/MET system Dihexa targets; it reached the Phase 3 LIFT-AD Alzheimer’s trial and, in 2024, missed its primary endpoint.

Two purpose-built, professionally manufactured drugs, tested in rigorous trials, both fell short of a decisive result. That does not prove either pathway is worthless — trials fail for many reasons — but it is a powerful caution against the fantasy that an unregulated version bought online will do what the polished pharmaceutical could not. When the best-resourced, best-controlled versions of a mechanism struggle, the research-chemical version is not a hidden shortcut. It is a bigger gamble with less oversight.

What Actually Works for Brain Fog & Cognitive Energy

Neither methylene blue nor Dihexa fixes the cause of brain fog, and that caveat matters more than either compound. If your thinking is foggy, the highest-yield moves are unglamorous and well-proven:

  • Rule out a medical cause. Persistent fog can flag B12, iron or vitamin D deficiency, thyroid disease, depression, sleep apnoea, menopause and more. A GP work-up beats any supplement.
  • Fix sleep first. Nothing restores cognitive energy like consolidated sleep — see insomnia & sleep deprivation. A metabolic tune-up cannot replace the night your brain actually needs.
  • Exercise. Aerobic activity is the most reliable natural driver of BDNF and mitochondrial health — it improves the very energy supply methylene blue is hoped to boost, for free.
  • Sort the fundamentals of fuel. Blood-sugar swings, dehydration, caffeine mismanagement and alcohol all drive fog far more commonly than any mitochondrial “dysfunction” a dropper can fix.
  • Be wary of both the dye and the peptide. Methylene blue is a real drug with a serious antidepressant interaction; Dihexa is an unproven research chemical with a c-Met concern. Neither is a casual add-on — the recurring theme of the Dihexa vs nootropics comparison and the stacking guide.

Methylene Blue: Practical, Honest Cautions

If methylene blue is something you are considering, the responsible framing is that it is a medicine, not a wellness powder, and it should be discussed with a clinician — particularly given how many people it should not touch. The interactions are the headline: because methylene blue inhibits monoamine oxidase A, combining it with SSRIs, SNRIs, tricyclic antidepressants, MAOIs, triptans, tramadol or other serotonergic drugs can precipitate serotonin syndrome, a potentially life-threatening reaction that prompted an FDA drug safety communication. Given that nearly nine million people in the UK take antidepressants, this is not a fringe concern. People with G6PD deficiency can suffer dangerous red-blood-cell breakdown. And the “methylene blue” sold for biohacking is frequently laboratory or industrial grade, which can contain heavy-metal and other contaminants and must never be swallowed. High doses turn the picture the wrong way entirely: above the low-dose window, methylene blue becomes a pro-oxidant and can impair rather than help. It also stains everything (including urine) blue. This site does not sell it and has no stake in whether you take it — this is general information, not medical advice.

Who Should Steer Clear

For the specific goal of clearing brain fog or boosting cognitive energy, the honest position is that neither of these is a first move. Beyond that, methylene blue should be avoided by anyone taking serotonergic medication (especially antidepressants, MAOIs, triptans or tramadol), anyone with G6PD deficiency, anyone pregnant or breastfeeding, and anyone who cannot verify genuine pharmaceutical-grade sourcing. And Dihexa should be avoided altogether by:

  • Anyone with a personal or family history of cancer or any proliferative condition, given the pro-proliferative c-Met mechanism.
  • Anyone who is immunosuppressed, in whom a pro-growth signal carries added risk.
  • Anyone pregnant, breastfeeding or planning pregnancy.
  • Anyone taking multiple medications without clinician oversight of an unlicensed addition.
  • Anyone who has not first had a proper work-up for the treatable causes of brain fog listed above.

The Bottom Line

Methylene blue is one of 2026’s biggest wellness stories, and unlike most viral nootropics it is not vapour: it has a real mitochondrial mechanism, a licensed-medicine history, a supportive 2016 human fMRI study and a Phase 3 drug lineage in TauRx’s hydromethylthionine. On every one of those measures it out-evidences Dihexa, which sits at the opposite end of the spectrum — an intriguing synaptogenic mechanism with no completed human trials for cognition, an unknown safety profile, a pro-proliferative c-Met flag, and a closest clinical relative that failed its Alzheimer’s Phase 3. But “better than Dihexa” is a low bar, and it hides the real point: methylene blue is a genuine drug with a genuine, common, dangerous antidepressant interaction and a purity problem, not a casual supplement to microdose because a podcast said so. If your aim is a clearer, more energetic mind, the order is the same as ever: fix sleep, move your body, sort your fuel, treat any medical cause — and keep the blue dropper and the unlicensed peptide alike well down the list, and never without a clinician’s eyes on them. As always on this site: the unglamorous, well-studied path wins, and the hyped shortcut comes last.

Frequently Asked Questions

Does methylene blue help with brain fog?

There is a plausible mechanism and one suggestive human study, but no strong proof. A 2016 Radiology fMRI study found a single low dose raised activity in attention and memory networks and lifted memory retrieval ~7% in healthy adults. Methylene blue genuinely boosts mitochondrial energy production, which is why biohackers use it — but it will not fix an underlying cause of fog, its human cognitive evidence is thin, and it carries a serotonin-syndrome risk. It is better studied than Dihexa, but it is not a proven cure.

Is methylene blue or Dihexa better for cognitive energy?

Methylene blue has the more coherent story — a clear mitochondrial mechanism, a licensed-medicine history, good blood-brain-barrier penetration and a human fMRI study. Dihexa is an unlicensed research chemical with no completed human cognition trials and a c-Met safety concern. But neither is a first-line answer, and methylene blue’s antidepressant interaction and purity issues mean it is not a casual supplement either.

How does methylene blue work in the brain?

At low doses it acts as an alternative electron carrier in the mitochondrial electron transport chain, feeding electrons to cytochrome c oxidase (Complex IV) and raising ATP production, cerebral oxygen use and blood flow. It is also an antioxidant and inhibits tau aggregation. This is energy-and-metabolism tuning, quite different from Dihexa’s proposed HGF/c-Met synapse building — power supply versus rewiring.

What did the methylene blue Alzheimer’s trials show?

Its tau-inhibitor derivative hydromethylthionine (HMTM/LMTM, TauRx) reached Phase 3, including LUCIDITY, and TauRx submitted a UK MHRA marketing application in July 2024. Results are contested: the drug missed conventional endpoints but showed a sustained low-dose signal that reviewers debate. Even that disputed data is far more rigorous than anything that exists for Dihexa.

Is methylene blue safe, and what are the risks?

Pharmaceutical methylene blue is well characterised at medical doses, but three cautions matter for cognitive use: it inhibits MAO-A, so mixing it with SSRIs/SNRIs, triptans, tramadol or MAOIs can cause serotonin syndrome (an FDA warning); it can cause haemolysis in G6PD deficiency; and online product is often non-pharmaceutical grade. This is general information, not medical advice — and this site does not sell methylene blue.

Can I stack methylene blue and Dihexa together?

This site does not recommend Dihexa for brain fog, so it does not recommend stacking it with anything, including methylene blue. Combining an MAO-A-inhibiting dye with an unlicensed peptide that carries a c-Met concern layers two different risk profiles with no evidence of benefit. See the stacking guide for the wider caution.

External Authoritative Sources Cited

Editorial statement: This article is part of a rolling 2026 clinical-context review series examining where Dihexa sits in the evidence hierarchy for specific concerns. We are not clinicians, and we do not sell methylene blue or any supplement. This page is for education and is not medical advice. See the About page for our editorial approach and the disclaimer for legal scope. If brain fog is affecting your daily life, please speak to your GP.